Comparison of contrast echocardiography with single-photon emission computed tomographic myocardial perfusion imaging in the evaluation of patients with possible acute coronary syndromes in the emergency department

Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017

Contrast echocardiography is widely used in cardiology. It is applied to improve image quality, reader confidence and reproducibility both for assessing left ventricular (LV) structure and function at rest and for assessing global and regional function in stress echocardiography. The use of contrast in echocardiography has now extended beyond cardiac structure and function assessment to evaluation of perfusion both of the myocardium and of the intracardiac structures. Safety of contrast agents have now been addressed in large patient population and these studies clearly established its excellent safety profile. This document, based on clinical trials, randomized and multicentre studies and published clinical experience, has established clear recommendations for the use of contrast in various clinical conditions with evidence-based protocols.

Contrast echocardiography: evidence for clinical use

The failure of echocardiography to give diagnostically useful information in a significant proportion of patients has led to the development of specific contrast agents to enhance imaging. Suitable contrast media must have the ability to modify ultrasound characteristics, be capable of crossing the pulmonary capillary bed, show stability over the duration of a procedure, offer low blood solubility with low toxicity and be rapidly eliminated. The current generation of ultrasound contrast agents comprises microbubbles of a high molecular-weight gas encapsulated in a shell of phospholipid or protein. A review of the clinical evidence shows that these agents are clinically effective in enhancing echocardiographic imaging. They enable the rescue of failed procedures, often sparing patients from invasive tests, but appear not to add to the burden of side effects. Indeed, the benefits of using contrast agents in stress echocardiography have been recommended in recently published American Society of Echocardiography guidelines. Myocardial contrast echocardiography has now developed to the stage where assessment of myocardial perfusion for the detection of coronary artery disease is possible with the same diagnostic accuracy as radionuclide imaging. However, in comparison with the latter technique, it is less expensive, is more portable, and avoids the use of ionizing radiation. It is precisely the ability of myocardial contrast echocardiography to simultaneously assess function and perfusion at the bedside that has given it a unique role in clinical practice. This review provides an overview of the clinical evidence supporting the efficacy of contrast echocardiography in the assessment of myocardial structure, function, and perfusion.

Three-Dimensional Echocardiographic Evaluation of Myocardial Perfusion

One of the most intriguing developments in ultrasound imaging of the heart was the use of contrast media to assess myocardial perfusion, which sparked tremendous interest and over the years generated a significant body of research. Although most published work has been based on the use of contrast for 2D perfusion imaging, there are a few recent studies aimed at exploring the idea of 3D assessment of myocardial perfusion, which has the potential to overcome many of the limitations of the 2D methodology. We provide a brief overview of the 2D work that provided the scientific basis for the emerging 3D methodology and discuss the unique features and promises as well as the challenges posed by this novel approach.

Clinical utility of contrast-enhanced echocardiography

Over the past three decades, echocardiography has become a major diagnostic tool in the arsenal of clinical cardiology for real-time imaging of cardiac dynamics. More and more, cardiologists' decisions are based on images created from ultrasound wave reflections. From the time ultrasound imaging technology provided the first insight into a human heart, our diagnostic capabilities have increased exponentially as a result of our growing knowledge and developing technologies. One of the most intriguing developments that brought about a decade-long combination of expectations and disappointments was the introduction of echocardiographic contrast agents. Despite repeated waves of controversy regarding the readiness of this technology for clinical use, it has overcome multiple hurdles and currently provides useful clinical information that helps cardiologists to diagnose heart disease accurately. Since the initial reports on the use of ultrasound contrast media such as agitated saline or renografin, the major advances in the field of contrast echocardiography have included (1) the development of stable perfluorocarbon-filled microbubbles, frequently referred to as second-generation contrast agents; and (2) the development of contrast-targeted nonlinear imaging modes, such as harmonic imaging, pulse inversion, and power modulation, which allow consistent real-time visualization of these agents. These contrast agents in conjunction with the new imaging technology constitute powerful tools that improve our ability to evaluate left ventricular function and myocardial perfusion, and allow differential diagnosis of thrombi and intravascular masses. In this manuscript, we briefly review some of the literature that has provided the scientific basis for the use of echocardiographic contrast agents in the context of these important variables.

Myocardial Contrast Echocardiography Evolving as a Clinically Feasible Technique for Accurate, Rapid, and Safe Assessment of Myocardial Perfusion

Intravenous myocardial contrast echocardiography (MCE) is a recently developed technique for assessment of myocardial perfusion. Up to now, many studies have demonstrated that the sensitivity and specificity of qualitative assessment of myocardial perfusion by MCE in patients with acute and chronic ischemic heart disease are comparable with other techniques such as cardiac scintigraphy and dobutamine stress echocardiography. Furthermore, quantitative parameters of myocardial perfusion derived from MCE correlate well with the current clinical standard for this purpose, positron emission tomography. Myocardial contrast echocardiography provides a promising and valuable tool for assessment of myocardial perfusion. Although MCE has been primarily performed for medical research, its implementation in routine clinical care is evolving. This article is intended to give an overview of the current status of MCE.

Usefulness of real-time myocardial perfusion imaging in the evaluation of patients with first time chest pain

In patients who have acute coronary syndrome (ACS), rapid and accurate risk stratification is crucial. Real-time myocardial contrast echocardiography (MCE) extends the evaluation of wall motion abnormalities by assessing myocardial perfusion. We investigated whether MCE could contribute to clinical and biochemical markers in identifying patients who have ACS when presenting to the emergency department. Consecutive patients (n = 100) who presented with first occurrence of chest pain underwent MCE to evaluate myocardial perfusion. Contrast images were also analyzed quantitatively off-line by measuring peak signal intensity (A) and slope of signal intensity increase (beta) in 16 myocardial segments. Thirty-seven of 100 patients had ACS. MCE showed perfusion defects in 9 of 12 patients (75%) who had unstable angina and had high-grade stenotic lesions on an angiogram that were missed by assessment of troponin T. MCE identified all 6 patients who had non-ST-elevation myocardial infarction and no initial increase in troponin T and 17 of 19 patients who had non-ST-elevation myocardial infarction and an initial increase in troponin T. In 2 patients who had chest pain and increased troponin T, MCE excluded ACS by identifying perimyocarditis as the underlying cause. Multivariate logistic regression analysis showed that MCE was the strongest predictor of ACS, thus adding significant diagnostic value to conventional tests. Initial perfusion defect size correlated strongly with increased troponin T at 96 hours (r = 0.73, p <0.001) and with ejection fraction at 4 weeks of follow-up (r = -0.79, p <0.001). Thus, our data suggest that MCE can accurately identify patients who have ACS.

Recent advances in echocardiography

Important recent developments have occurred in echocardiography that are already being used clinically. Portable ultrasound devices that weigh less than five pounds are capable of performing a complete bedside echo exam. An intracardiac echocardiographic catheter has recently been introduced that can be placed intracardiac via a vein and navigated within right heart chambers to obtain detailed anatomical landmarks that guide catheter based interventional procedures such as intracardiac ablation and closure of atrial septal defects and patent foramen ovale. Tissue Doppler imaging is finding its role in detecting mechanical asynchrony in patients with congestive heart failure who might benefit from biventricular pacing. The availability of real-time 3D echocardiography has for the first time made assessment of complex cardiac anatomy possible. This review discusses each of these new developments and their potential impact on the practice of echocardiography and cardiology in general.